Breaking down the barriers to drug development
9 Jan 2015
Dr. Francoise Meunier, EORTC Director General, Sir Michael Rawlins, former chair of NICE, and Robert Strieter, Novartis Institutes for Biomedical Research discuss translational medicine in respiratory disease in Prof. Peter Barnes’ latest instalment of ERS Vision. The film looks at ways to break down the barriers that obstruct and delay the development of new medicines at every stage of the discovery process.
Leading experts in the field tackle issues such as data protection, risk management, protocol development and European regulations, and emphasise the importance of developing active collaborations between the different stakeholders involved in the drug development process.
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023
